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Summan For successful photodynamic diagnosis (PDD) and effective photodymamic therapy (PDT) with the
clinically used 'photosensitiser' 5-aminolaevulinic acid (ALA). knowledge of the maximal fluorescence intensity
and of the maximal tumour-host tissue fluorescence ratio following systemic or local application is required.
Therefore, time course and type of porphyrin accumulation were investigated in neoplastic and surrounding
host tissue by measuring the kinetics and spectra of ALA-induced fluorescence in vivo Experiments were
performed in the amelanotic melanoma A-Mel-3 grown in the dorsal skinfold chamber preparation of Syrian
golden hamsters. The kinetics of fluorescent porphyrins was quantified up to 24 h after i.v. injection of
100 mg kg-'. 500 mg kg-' or 1.000 mg kg-' body weight ALA by intravital fluorescence microscopy and
digital image analysis (n = 18). In separate experiments fluorescence spectra were obtained for each dose by a
simultaneous optical multichannel analysing device (n = 3). A three-compartment model was developed to
simulate fluorescence kinetics in tumours. Maximal fluorescence intensity (per cent of reference standard;
mean±s.e.) in the tumour arose 150min post injection (p.i.) (I.000mgkg-'. 109±34%;: 500mgkg-',
148 ± 36%) and 120 min p.i. (100 mg kg- '. 16 ± 8%). The fluorescence in the surrounding host tissue was far
less and reached its maximum at 240 min (100 mg kg-'. 6 ± 3%) and 360 min p.i. (500 mg kg- '. 50 ± 8%) and
(1.000 mg kg-'. 6 ± 19%). Maximal tumour-host tissue ratio (90:1) was encountered at 90 mn after injection
of 500 mg kg-'. The spectra of tissue fluorescence showed maxima at 637 nm and 704 nm respectively After
300 min (host tissue) and 360 min (tumour tissue) additional emission bands at 618 nm and 678 nm were
detected. These bands indicate the presence of protoporphyrin IX (PPIX) and of another porphyrin species in
the tumour not identified yet. Tumour selectivity of ALA-induced PPIX accumulation occurs only during a
distinct interval depending on the administered dose. Based on the presented data the optimal time for PDD
and PDT in this model following intravenous administration of 500 mg kg-' ALA would be around 90 min
and 150 min respectively. The transient selectivity is probably caused by an earlier and higher uptake of ALA
in the neoplastic tissue most likely as a result of increased vascular permeability of tumours as supported by
the mathematical model.
In 1955 the first report on transitory hypersensitivity to
sunlight following exogenous administration of 5-amino-
laevulinic acid (ALA) was published (Scott. 1955). By injec-
ting ALA subcutaneously into the back of rats Jarret et al.
(1956) could support this observation. In addition, Berlin et
al. (1956a,b) described light hypersensitivity after ingestion of
ALA by human subjects to study the metabolism of ALA. At
that time preferential localisation of porphyrins in neoplasms
of tumour-bearing animals and subsequent photodynamic
reactions due to light irradiation had already been shown
(Policard, 1924: Auler & Banzer, 1942). Thirty years later
Kennedy et al. (1990) made use of this knowledge and
treated the first neoplastic skin lesions using topically applied
ALA as 'photosensitiser'.
In higher organisms the first step in haem biosynthesis, i.e.
the formation of ALA, and the last three steps, i.e. the
conversion of coproporphyrinogen to haem, take place in the
mitochondria. Thus haem synthesis occurs only in cells con-
taining mitochondria and is absent in cells lacking mito-
chondria, such as erythrocytes (Williams, 1990). The
rate-limiting step in endogenous porphyrin production, i.e.
formation of ALA, is bypassed when ALA is either given
systemically or applied locally in excess amount (Kennedy et
al., 1990; Kennedy & Pottier, 1992; del C. Batile, 1993).
Subsequently, depending on the cells' enzyme proffle, the
intracellular accumulation of photosensitising porphyrins
occurs (Pottier et al., 1986, Divan's et al., 1990; Kennedy et
al., 1990; Loh et al., 1992, 1993), providing the basis for
photodynamic diagnosis and treatment of superficial malig-
nancies.
ALA-induced fluorescence and accumulation of photosen-
sitising porphyrins are already used clinically for photo-
dynamic diagnosis (PDD) and therapy (PDT) of various
tumours (Kennedy et al., 1990; Wolf & Kerl, 1991: Baum-
gartner et al., 1993; Grant et al., 1993; Wolf et al., 1993).
However, the kinetics of ALA-induced fluorescence in
tumours has not yet been studied in vivo.
So far, ALA-induced fluorescence has been measured in
histological sections of normal colon and of a colon car-
cinoma showing high mucosa fluorescence (Bedwell et al.,
1992). The kinetics has also been determined ex vivo by
porphyrin extraction from a mammary carcinoma (Peng et
al., 1992). Moreover, PDD and PDT have been performed
using the induced porphyrins without knowledge of the time
course of fluorescence intensity in neoplastic tissue and of the
optimal tumour-surrounding tissue fluorescence ratio
(Divaris et al., 1990; Kennedy et al., 1990; Bedwell et al..
1992; Wolf et al., 1993). This could be an explanation for
heterogeneous responses to PDT with ALA or different
tumour types reported so far (Wolf et al., 1993). The impor-
tance of further investigations of ALA-induced fluorescence
kinetics is emphasised in order to determine the optimal time
for PDT (Szeimis et al., 1994). Therefore a model allowing in
vivo investigation in conscious tumour-bearing animals over a
prolonged time (Endrich et al., 1980) was chosen to deter-
mine intensity and time course of ALA-induced fluorescence
in neoplastic and surrounding host tissue after intravenous
administration of ALA. In addition, a mathematical model
was developed to describe the mechanism of ALA-induced
fluorescence in solid tumours.
Methods
Animals and tumour model
Male Syrian Golden hamsters of 60-70 g body weight (b.w.)
were used, fitted with titanium chambers. Amelanotic melan-
omas (Fortner et al., 1961) were implanted (injection of
approximately 2 x Io0 A-Mel-3 cells) in the dorsal skinfold
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chamber. Injection of cells was performed 48 h after surgical
preparation of the chambers, when they showed an intact
microcirculation (for details see Endrich et al., 1979; Endrich
et al., 1980, Asaishi et al., 1981). The host tissue consists ofa
thin skin muscle, subcutaneous adipose tissue and dermis
(Endrich et al., 1980). Six to eight days later fluorescence
microscopy and spectroscopy were performed when a non-
haemorrhagic tumour was established (mean tumour
diameter 6mm). Twenty-four hours before the injection of
ALA permanent indwelling catheters (PE 10, inner diameter
0.28 mm) were implanted under anesthesia (pentobarbital,
50mg kg-' b.w.) into the right jugular vein. Twenty-one
animals were included in the study.
Preparation andadministration ofALA
ALA as the hydrochloride salt (MW 168) was obtained from
Merck (Darmstadt, Germany), dissolved in phosphate-
buffered saline (pH 6.5) at a concentration of 100mg ml-'
and used immediately. ALA was mini intravenously
in doses of I00mg kg-', 500 mg kg-' or 1,000mg kg-' b.w.
The conscious animal did not show any signs of discomfort
during injection of the buffered solution as previously
reported by Edwards et al. (1984).
In vivofluorescence microscopy
The conscious hamster was positioned in a Perspex tube on a
custom-made stage (Effenberger, Munich, Germany) under a
modified Leitz microscope (Orthoplan, Type 307-143003/
51466, Leitz, Munich, Germany). To enable subtraction of
tissue autofluorescence intravital microscopy was performed
before intravenous injection of ALA (n = 6 for each dose).
At 1, 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 and
360min and 24h after injection ALA-induced fluorescence
was registered.
Fluorescence was excited at 355-425 nm for 2 s at a power
density of 200-300 #Wcm-2 (100 W HBO mercury lamp)
measured by a wavelength-correcting diode detector ('Lab-
master', Coherent, Auburn, USA). Emission fluorescence was
detected above 610 nm. Fluorescence images were recorded
by a silicon-intensified target video camera (C2400-08,
Hamamatsu, Herrsching, Germany), which was previously
calibrated to assure linearity by measunng emitted fluo-
rence of used standard (Impregum F, Seefed Germany)
through different grey filters at all sensitivity levels of the
camera. Acquired fluorescence images were digitally inte-
grated by an image analysis system and stored on hard disk
(IBAS 2000, Kontron, Eching, Germany).
Fluorescence intenties were measured densitometrically
off-line after subtraction of tissue autofluorescence. All
fluorescence values are given in per cent of the values
obtained from a reference fluorescne signal (per cent stan-
dard) inserted into each chamber preparation (Impregum F,
Seefekl, Germany; for details see Leunig et al., 1993). Briefly,
the geometric resolution of the digitised images was
512 x 512 pixels by a densitometric resolution of 255 grey
values. Photosensitiser fluorescence in tumour and host tissue
was determined in areas (50 x 50pm2) positioned in tumour
and surrounding host tissue by densitometnc mesurement.
Areas of measurement were chosen in a transillumination
image of each chamber preparation. Thus a mask was
created without knowledge offluorescence localisation, which
was then used for neasurements in the fluorescence images at
all observation times. Spatial inhomogeneities of the light
source and the camera sensitivity were compensated by
shading correction with the image analysis system.
fn vivofluorescence spectroscopy
Recording of emission spectra provides an additional means
to confirm presence and to determine the type of porphyrin
synthesised in neoplastic and normal tissue following i.v.
administration of ALA, since porphyrins exhibit specific
fluorescence profiles. Fluorescence light was transmitted via a
single fused-silica fibre (HCN 600) to an intensified optical
multichannel analyser (O/SMA 3, Spectroscopy Instruments,
Gilching, Germany). The analyser works linearly from 1 to
10,000 counts as proven by measurements of wavelength
intensity of a helium-neon laser (632 nm) through different
grey filters. To block scattered excitation light from the
detector, a long-pass, low-fluorescence filter (KV 550, Schott,
Germany) was used. Fluorescence was excited for 2 s at a
power density of 200-300lzWcm-2 (100W XBO mercury
lamp) at 355-425 nm. Intensity (arbitrary units, a.u.) was
recorded in the spectral range between 590 and 750 nm with
a resolution of 3 nm. Autofluorescence was not subtracted.
Fluorescence emission spectra were registered in vivo from
tumour and surrounding host tissue after injection of
100mgkg-', 500mgkg-' or 1,000mgkg-'b.w. ALA.
Recording times were the same as for intravital microscopy
but limited to 420min.
Statistics
Statistical analysis of the data was performed using the
Friedman test for multiple comparison of ranks of related
samples and the Kruskal-Wallis test ofindependent samples.
Single comparisons of related samples were done by the
Wilcoxon matched pairs test. In all cases, differences were
regarded as significant if P<0.05.
Resis
In vivofluorescence microscopy
The fluorescence kinetics of formed porphyrins after i.v.
injection of different doses of ALA is shown in Figure 1.
Porphyrin fluorescence in the tumour was detectable as early
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Figwe 1 Quantitative fluorescence kinetics determined by means
of intravital microscopy in tumour (A) and surrounding host
tissue (0) as function of time after i.v. administtion of
lOOmgkg-' (a), 500mgkg-' (b) and 1,00Omgkg' (c) ALA.
Fluorescence intensity in tumours was significantly higher during
a limited time interval lasting maximally from 15 min to 240min
after injection of ALA (mean ± s.e.; 'P<0.05, TU vs HO; n = 6
for each dose).
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Table I ALA-induced fluorescence in tumour and host tissue
ALA (mgkg-') TUL,, (per cent standard) HO,,,, (per cent standard) Tl'HO
100 16 ± 6 6 ± 2 12:1
500 149±33b 50+ 7 ab 90:1
1000 109 ± 34c 68± 19c 78:1c
TU,W (per cent standard), maximum fluorescence intensity in tumour (mean ± s.e.);
HO,, (per cent standard), maximum fluorescence intensity in host tissue (mean ± s.e.);
TU HO, highest tumour/host tissue fluorescence ratio recorded. aP<0.05 (100mg kg-' vs
500 mg kg-1). bp<0.05 (TUW,,,,S vs HO,). cP<0.05 (100mgkg-' vs 1,O00mgkg-').
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FJgwe 2 Tumour-host tissue fluorescence ratio. Values are
mean of the ratio of individual animals ± s.e. (CP<0.05,
l00mgkg-' vs 500mgkg-'; tP<0.05, 100mgkg-' vs
1,O00mgkg-'; n=6 for each dose). 0, ALA l00mg kg-'; A,
ALA 500mgkg-'; A. 1,000mg kg-'.
as 15 min p.i. when 500 or 1.000 mg kg-'b.w. was admin-
istered, whereas first fluorescence in the surrounding normal
tissue arose at 1 h. Maximal fluorescence intensities in the
tumour were measured at 120 min p.i. (16 + 8%.
100 mg kg-') and at 150 min p.i. (109 ± 34%, 1,000 mg kg-',
148 ± 36%, 500 mg kg-'). Highest absolute fluorescence in
neoplastic tissue was reached after administration of
500 mg kg-' (Table I). Fluorescence in the surrounding host
tissue was far less than in the tumour, reaching a maximum
after 240 min (6 ± 3%. 100 mg kg-') and 360 min p.i.
(68± 19%, l000mgkg-'; 50+8%, 500mgkg-'). The
highest absolute fluorescence in surrounding tissue was
measured after 1,000 mg kg-' b.w.
Fluorescence decreased constantly after reaching the maxi-
mum and was barely detectable after 24 h p.i. either in the
tumour (0.8 ± 0.8%, 100 mg kg-'; 2.2 ± 1.7%, 500 mg kg-';
9.7 ± 2.2%. 1.000 mg kg-') or in the surrounding host tissue
(0.9±0.9%. l00mgkg-'; 1.4+0.7%. 50Omgkg-';
8.9±4.2%, l,000mgkg-').
For optimal diagnosis or effective therapy of malignancies
in our model, tumour-host tissue ratios were calculated for
the administered doses (Figure 2). The optimal ratio was
found at 60min for 100mg kg-', at 90min for 500mg kg-'
and at 120 min for 1000 mg kg-'. The maximal
tumour-normal tissue ratio was calculated for 500 mg kg-'
as 90:1. Ratios obtained after injection of 100 mg kg-' and
1.000 mg kg-' were 12:1 and 78:1 respectively (Table I).
The maximal fluorescence intensities indicating the highest
sensitiser concentration in tumour and surrounding host tis-
sue are shown in Table I. A significant difference between
maximal photosensitiser concentration in tumour and max-
imal concentration in host tissue was measured after adminis-
tration of 500 mg kg-' ALA. The maximal porphyrin
fluorescence (500 mg kg-') in neoplastic tissue could not be
increased by a twofold higher dose of ALA (1,000 mg kg-'),
indicating likely saturation. However, fluorescence intensity
was still increasing in surrounding host tissue. Significantly
higher maximal fluorescence intensities were measured after
administration of 500 or 1,000mg kg' in comparison with
100 mg kg' in neoplastic as well as in host tissue.
It is noteworthy that there was heterogeneity of
fluorescence not only when individual tumours were com-
pared, as indicated by the high standard error (Figure 1), but
also within tumours shown in the fluorescence images (Figure
3).
In vivofluorescence spectroscopy
The emission spectra from the tumour exhibited spectral
emission bands with maxima at 637 and 704 nm (Figure 4)
and with a time delay in the surrounding host tissue.
indicating the presence of protoporphyrin IX. Recording of
spectra over 7 h enabled comparison of the time course of
fluorescence intensity obtained by fluorescence microscopy
and spectroscopy. Maximal fluorescence measured by means
of fluorescence spectroscopy arose in the neoplastic tissue at
150 min p.i. (500 mg kg-'; 1,000 mg kg-') and 120 min p.i.
(100 mg kg-'). Spectroscopic recordings revealed the same
kinetics in neoplastic and host tissue as observed by
fluorescence microscopy (data not shown).
Moreover, peaks at 618 nm and 678 nm arose at 360 min
following ALA injection in the tumour and at 300 min in the
host tissue, indicating the presence of another fluorescent
compound (Figure 4).
For the first time the in vivo fluorescence kinetics together
with the spectral characteristics of ALA-induced endogenous
porphyrin accumulation in tumour and surrounding host
tissue have been measured. The determination of the exact
time course of porphyrin fluorescence in tumours is the basis
for effective PDD and PDT, making use of the highest
fluorescence intensity in neoplastic tissue and the optimal
tumour-host tissue fluorescence ratio. In addition, elucida-
tion of the underlying mechanism that leads to tumour selec-
tivity might result in a fundamental improvement in this
therapeutic modality.
Intravital microscopy of tumours grown in transparent
skin chambers is a highly valuable, established method for
the study of photosensitiser localisation kinetics (Leunig et
al., 1993). Using this model photosensitising drugs can be
visualised not only directly at the microscopic level by their
specific fluorescence emission but also without artifacts
caused by sacrificing the animals for ex vivo investigation.
Continuous in vivo measurements of fluorescence in the iden-
tical tumour are in particular advantageous using an
endogenous photosensitiser, which might be formed at vary-
ing times and in varying amounts in different tumours of the
same type. Linear correlation of fluorescence intensity and
drug concentration in the tissue is a prerequisite guaranteed
in this model because of the optical characteristics of the flat,
well-demarcated tumour and the optical systems used
(Armenante et al., 1991; Leunig et al., 1993).
For systemic administration of ALA it is necessary to
buffer the solution since higher volumes of an acidic solution
might alter systemic blood pH, which may result in a change
in photosensitiser uptake in tumour cells (Benet & Sheiner,
1980; Brault, 1990). In addition buffering the solution will
prevent severe pain in the conscious hamster as well as
hypotension and bradycardia (Edwards et al.. 1984). Concer-
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Fgwe 3 Transillumination (a) and fluorescence images of the amelanotic melanoma in skinfold chamber at 5 min (b), 90 min (c)
and 360 min (d) after i.v. injection ofALA. Note the intra-tumour heterogeneity offluorescence. The two fluorescent squares at the
top of the chamber represent the reference fluorescence signals (chamber diameter II mm).
ning toxicity of the administered doses of ALA, animals did
not show any signs of changed behaviour regarding activity
or discomfort during the observation period. In addition,
near-neutral or basic pH may result in a change in the ALA
molecule, indicated by yellow discoloration of the solution
with time. Therefore it is very important to apply the
prepared ALA solution imediately after preparation.
Different doses of ALA were chosen according to the early
findings of Sima et al. (1981) and Pottier et al. (1986). The
need for higher doses of ALA to obtain pronounced
fluorescence, in contrast to the findings of Bedwell et al.
(1992) and Peng et al. (1992), could be the result of the high
metabolic capacity of the hamster liver (Berr et al., 1993).
Nevertheless, a general decreased capacity of the amelanotic
melanoma to synthesise protoporphyrin IX has not been
excluded. However, Rebeiz et al. (1991) have shown that
rapidly growing and multiplying cells such as A-Mel-3 tend
to accumulate more tetrapyrroles owing to an increased
demand for haem for cytochrome formation.
The recorded emission spectra of tumour and host tissue
show the typical emission bands of protoporphyrin XI in
tissue with maxima at 637 and 704 nm being in accordance
with the literature (Divaris et al., 1990; Bedwell et al., 1992;
Kennedy & Pottier, 1992; Loh et al., 1993). Interestingly,
after 5 h new peaks arose in the host tissue at 618 nm and
678 nm, respectively, after administration of 500 mg kg-' and
1,000 mgkg-' b.w. and appeared also in the tumour at
360 min (Figure 4). This might reflect the formation of
another fluorescent compound, probably uro- or copropor-
phyrin, not yet identified. It has been shown that the amount
and type of porphyrin formed varies depending on the cell
line (C. Fritsch, personal communication). Whether this new
porphyrin is synthesised in the amelanotic melanoma, in the
surrounding host tissue or elsewhere in the organism has not
yet been determined.
In the amelanotic melanoma tissue porphyrin fluorescence
was registered as early as 15 min p.i. Peng et al. (1992) could
extract PPIX from a mammary carcinoma 1 h after
peritoneal injection of ALA. However, they did not inves-
tigate porphyrin accumulation at earlier times. Three hours
after ALA injection they found that the porphyrin content
was already mark-edly decreased, thus probably missing the
period of highest PPIX concentrations in neoplastic tissue
between I h and 3 h, as we have shown. In our model the
highest host tissue fluorescence was found at 4 h p.i.
(100mgkg-1) and 6hp.i. (500 and 1,000mgkg-'). A
delayed maximum fluorescence intensity in normal tissue as
compared with neoplastic tissue was also observed in the
study of Bedwell et al. (1992). They found maximal
fluorescence intensity in normal colon 4 h after intravenous
injection of ALA. Also, porphyrin extraction of surrounding
normal skin revealed a later maximum of PPIX than in the
mammary carcnoma (Peng et al., 1992).
In amelanotic melanoma, as in other tumours, structural
peculiarities of microvessels, such as holes in the endothelial
lining, discontinuous basal membrane and direct contact of
tumour cells with the microvascular lumen (Hammersen et
al., 1983), are associated with high transcapillary filtration
compared with normal microvasculature (Endrich et al.,
1983). Investigations by Gullino et al. (1966) have shown that
the concentrations of low molecular weight solutes, such as
free amino acids, are higher in tumour interstitial fluid than830 C. ABELS et al.
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Fige 4 Fluorescence emission spectra (500 mg kg'' b.w. ALA)
from tumour (- - -) and surrounding host tissue (-
exhibiting the typical PPIX profile in tissue. At 390 min new
peaks at 618 nm and 678 nm are easily visible, indicating the
presence of another fluorescent compound.
in plasma. This is because of the enhanced permeability of
tumour microvessels (Jain, 1987). Thus, it seems very likely
that the earlier appearance of fluorescence in tumours is
mainly the result of a faster exchange of ALA, a five-carbon
amino acid, from the intravascular into the interstitial space
and consequently earlier uptake into tumour cells than in
host cells. Since a considerable amount of ALA is rapidly
excreted in the urine (Berlin et al., 1956a.b) and taken up by
organs with a high metabolic activity for ALA, such as liver
or kidney (Shimizu et al., 1978), plasma levels will decrease
rapidly. The higher fluorescence values in the tumour as
compared with the surrounding host tissue might thus reflect
the faster uptake of ALA in neoplastic cells at times of
higher intravascular concentrations.
As mentioned above, the plasma level of ALA decreases
with time. Thus less fluorescence will be formed in host tissue
in vivo than could be synthesised from a given dose of ALA
in cell culture experiments simulating a constant plasma level.
Also, Nugent and Jain (1984) have shown that small
molecules (sodium fluorescein, MW 376) such as ALA have
higher diffusion coefficients in neoplastic tissue than in nor-
mal tissue. Thus, it is not surprising that the highest absolute
fluorescence measured in the surrounding host tissue is less
(Table I) than in neoplastic tissue with its higher vascular
permeability and higher diffusivity (Gerlowski & Jain, 1986).
Based upon the in vitro model proposed by Jacques et al.
(1993), for the first time a mathematical model has been
developed (Figure 5) simulating in vivo fluorescence kinetics
by using least-square fits and a Marquardt algorithm (Bev-
ington, 1969). This improved model best fitted the
fluorescence kinetics of ALA-induced porphyrins in the well-
vascularised and fast-growing amelanotic hamster melanoma
(Dellian et al., 1993): a solid tumour is a pathophysiological
entity consisting of at least three compartments, namely vas-
culature, interstitium and tumour cells (Ribbert, 1904; Jain.
1991). Therefore a systemically administered anti-tumour
drug will reach its target after distnrbution in the intravas-
cular space, by transport across the microvascular wall into
the interstitial space (invasion constant ko) and by transport
across the cell membrane into the tumour cells (invasion
Figre 5 Three-compartment model to simulate fluorescence kinetics in tumours assuming that ALA PPIX are metabolised
eliminated following first-order kinetics. Invasion processes leading to increased cellular levels of PPIX are marked by white arrows
and elimination processes resulting in decreased cellular levels are marked by black arrows. P is the concentration of PPIX in
neoplastic cells at time t. with P(O) = 0. and MO is the ALA concentration immediately after exogenous administration (for detailed
explanation see Discussion).
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constant k,). Consequently. these invasion processes (white
arrows in Figure 5) lead to increasing concentrations of
porphyrins in neoplastic tissue after administration of ALA.
Once administered as a bolus, ALA is taken up particular-
ly by liver and kidney (Berlin et al., 1956a,b; Shimizu et al.,
1978) (evasion constant kr), resulting in decreasing plasma
concentration. The PPIX formed in the tumour is also
eliminated (evasion constant kA). Both mechanisms yield
reduced cellular levels of PPIX indicated by the black arrows
in Figure 5. It is assumed that elimination of ALA from
intravascular space is mainly governed by kA
AA(O) = Mo eAit (1)
where M is the concentration of ALA in the intravascular
space at time t and M0 is the ALA concentration following
intravenous administration after reaching equilibrium. Be-
cause of this assumption k,, could not be calculated. Inserting
equation (1), which reflects the elimination of ALA from the
intravascular space by uptake into other organs and excre-
tion, into the differential equation (2) leads to equation (3):
(2) dM
o-- [ekl M,Xt)
= 7 [e kxt e-l
where M, is the assumed concentration of ALA in the inter-
stitial space at time t, being 0 at t =0. Considering the
transport of the molecules from the interstitial into the int-
racellular space and subsequent formation of PPIX (equation
4) the final equation (5) will result, describing the in vivo
kinetics:
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P(t) = k (e-xt - e-k2) +-e 2 (e -elk)J (5)
k1-k.k -k, k -k,
where P is the concentration of PPIX in neoplastic cells at
time t, with P(O) =0. Since ALA does not fluoresce, only the
formed fluorescent porphyrins will be observed by intravital
microscopy. Moreover, the invasion constant k1 results from
transport into the cell, transport into mitochondria and
subsequent metabolisation to PPIX. As shown in Figure 6,
this three-compartment model (equation 5) yield a better
curve fit than the initial compartment model proposed by
Jacques et al. (1993) assuming decreasing intravascular ALA
concentration (equation 3).
Table II Invasion and evasion constants
ALA (mgkg-1) k, (s-') k2 (s- ) kr (s-1)
100 0.005± 0.01 0.02± 3.8 0.02± 4
500 0.02± 0.9 0.02± 0.8 0.008 ± 0.009
1000 0.007± 0.02 0.02± 0.4 0.02± 0.4
Metabolism of PPIX+ 0.02 0.005 0.008
Calculations by fit procedure for a three-compartment model. To
simulate reduced metabolism of PPIX owing to decreased ferrochela-
tase activity in neoplastic tissue, evasion constant k, was considered
to be 25% of calculated k, (500mg kg-'), whereas k, and k_ were
considered to be unchanged. ko could not be calculated (errors are
s.d.).
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Fiwe 6 Fluorescence kinetics in tumours as observed in vivo (0), as fitted according to the proposed three-compartment model
(- -) and as obtained using the model described by Jacques et al. (1993) assuming decreasing ALA concentration ( )
( 1000 mg kg-'. a, 500 mg kg '. b, 100 mg kg-', c. Possible time course of fluorescence appearance in tumours assuming reduced
evasion (k.) of PPIX as a result of decreased ferrochelatase activity in neoplastic tissue as result of fit procedure according to the
three-compartment model (d). Note the different ranges of ordinates.
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The mechanism of elimination of PPIX from the cells is
not yet clear. A reduced activity of the converting enzyme
ferrochelatase in tumour cells would result in a slow elimina-
tion of PPIX from neoplastic tissue, reflected by a small
evasion constant k2 (Table II). Subsequently, porphyrins
would be retained in the tumour. forning a later and higher
maximum of fluorescence in neoplastic than in surrounding
host tissue (Figure 6). However, the kinetics of ALA-induced
PPIX accumulation exhibits a very early maximum of
fluorescence in the amelanotic melanoma and a rapid
decrease in intensity before the fluorescence maximum in the
surrounding host tissue is reached (Figure 1).
Therefore one cannot conclude from the presented data
that earlier and greater formation of ALA-induced
endogenous fluorescence in neoplastic tissue is a specific
effect because of a reduced activity of the PPIX converting
enzyme ferrochelatase in neoplastic tissue, as discussed
elsewhere (Dailey & Smith. 1984; del C. Battle, 1993).
Moreover. the accumulation of porphyrins in tumours fol-
lowing systemic administration of ALA is mainly due to the
higher vascular permeability and diffusivity of neoplastic tis-
sue in general. Following topical application of ALA
accumulation of porphyrins in tumours might be due to not
only abnormal keratin overlying basal and squamous cell
carcinomas (Kennedy & Pottier, 1992), yielding reduced
mechanical resistance, but also to lower interstitial resistance
to the transport of molecules in neoplastic tissue (Nugent &
Jain, 1984).
Marked differences in fluorescence intensities are also visi-
ble within tumours (Figure 3). In contrast to exogenous
photosensitisers, ALA-induced photosensitising porphyrins
are formed within the tumour. Besides the regional mor-
phological differences in a tumour there is also regional
heterogeneity of oxygen. blood flow, energy phosphates and
pH (Endrich et al.. 1979; Vaupel et al., 1989; Kuhnle et al.,
1992) determining the metabolic microenvironment, which
might result in heterogeneous uptake and metabolism of
ALA in a tumour. A diminished activity of the protopor-
phyrin IX converting enzyme ferrochelatase in tumours or
metastases has been proposed to be responsible for increased
porphyrin concentrations in neoplastic tissue (Dailey &
Smith, 1984; Navone et al., 1990; Van Hillegersberg et al..
1992; del C. Battle. 1993). However, other investigators have
been unable to show accumulation of endogenously formed
porphyrins in diethylnitrosamine (DENA)-induced liver
tumours (Wainstok de Calmanovici et al., 1991) or reported
a normal haem synthesis in spontaneous mouse liver tumours
(Stout & Becker. 1990). The data regarding the capacity of
different tumour types to metabolise ALA remain incom-
plete. and differences between various tumour types should
be expected.
For the first time the kinetics and spectra of ALA-induced
fluorescence have been measured by quantitative intravital
fluorescence microscopy in tumour and surrounding host
tissue. Thus, this study provides basic information required
to understand the mechanism of porphyrin formation follow-
ing exogenous administration of ALA and to indicate the
optimal time for effective PDD and PDT according to this
model. Selective ALA-induced porphyrin fluorescence in
tumours occurs only during a limited interval lasting from
15 min up to 4 h after intravenous injection of ALA and by
far exceeds maximal tumour-host tissue fluorescence ratios
for Photofrin II or porphycenes measured in the same model
(Leunig et al., 1993). Twenty-four hours after intravenous
administration of ALA hardly any fluorescence was detec-
table in either the tumour or the surrounding host tissue
(Figure 1), thus general photosensitisation of patients after
systemic administration of ALA might be limited. The
highest tumour-host tissue ratio was recorded after a dose of
500 mg kg-' b.w. (90:1 at 90 min). Similar high selectivity of
PPXI is reported for bladder tumours determined during
fluorescence excitation in the Soret band following ALA
instillation into the bladder (Baumgartner et al., 1993). Tak-
ing maximal fluorescence intensity as an indicator of the
maximal tissue concentration of PPXI (at 150 mmn in
tumour), a therapeutic approach with 100 mg kg-' would be
questionable (Table I). For curative attempts higher doses
(500 mg kg-') should prove successful in our model, assum-
ing that PPIX is the decisive photosensitising agent. Taking
into account the data presented here, quantitative
fluorescence measurements of each tumour before PDT with
ALA should yield valuable information about local por-
phyrin accumulation allowing therapeutic failure of this pro-
mising therapeutic modality to be avoided.
Abbemvtioas ALA. 5-aminoaevulinic acid; PPIX. protoporphyrin
IX; PDT. photodynamic therapy: PDD. photodynamic diagnosis.
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